Immunitybio Inc (IBRX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $8.48 (+0.24%), Market cap $8.09B, 52-week low–high $1.98 ~ $11.55.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for
Financial statements, price targets, institutional (13F) holdings and related news for Immunitybio Inc are updated in real time on BlackAll Trade.
Immunitybio Inc trades at $8.48 (+0.24%). Real-time quotes and charts are available on BlackAll Trade.
Immunitybio Inc has a market cap of about $8.09B.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable